Tyrosine kinase inhibitor oral- OV-SPV2
Latest Information Update: 12 Jan 2017
At a glance
- Originator Unknown
- Developer OV-SPV2; Unknown
- Class Antineoplastics
- Mechanism of Action Protein-tyrosine-phosphatase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Cancer